Elbasvir/grazoprevir/uprifosbuvirAlternative Names: Elbasvir/grazoprevir/MK-3682; MK 3682/MK 8742/MK 5172; MK-3682A
Latest Information Update: 20 May 2016
At a glance
- Originator Merck & Co
- Class Antivirals; Macrocyclic compounds; Small molecules; Uracil nucleotides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 06 May 2016 Discontinued - Phase-II for Hepatitis C (PO) (Merck pipeline, May 2016)